Vita Life Sciences Ltd
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods. It markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands… Read more
Vita Life Sciences Ltd - Asset Resilience Ratio
Vita Life Sciences Ltd (VLS) has an Asset Resilience Ratio of 39.38% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Vita Life Sciences Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Vita Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$29.40 Million | 39.38% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$29.40 Million | 39.38% |
Asset Resilience Insights
- Very High Liquidity: Vita Life Sciences Ltd maintains exceptional liquid asset reserves at 39.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Vita Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Vita Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Vita Life Sciences Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Vita Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.90% | AU$21.50 Million | AU$71.89 Million | -2.21pp |
| 2023-12-31 | 32.11% | AU$19.20 Million | AU$59.81 Million | +24.68pp |
| 2022-12-31 | 7.42% | AU$3.85 Million | AU$51.80 Million | -5.81pp |
| 2021-12-31 | 13.23% | AU$5.99 Million | AU$45.27 Million | +2.03pp |
| 2020-12-31 | 11.21% | AU$4.38 Million | AU$39.10 Million | +5.43pp |
| 2019-12-31 | 5.77% | AU$2.11 Million | AU$36.51 Million | -24.86pp |
| 2018-12-31 | 30.63% | AU$10.94 Million | AU$35.72 Million | +17.52pp |
| 2017-12-31 | 13.11% | AU$4.32 Million | AU$32.95 Million | +7.82pp |
| 2016-12-31 | 5.30% | AU$1.71 Million | AU$32.36 Million | +0.24pp |
| 2015-12-31 | 5.05% | AU$1.64 Million | AU$32.39 Million | -- |